The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | Emerging strategies for the management of relapsed AML
Despite significant improvements in the management of patients with newly diagnosed acute myeloid leukemia (AML), many patients still relapse. In this video, Charles Craddock, CBE, FRCP, FRCPath, DPhil, University of Birmingham, Birmingham, UK, comments on strategies to both prevent and manage relapse post-transplant in AML. Prof. Craddock first notes the progress in FLT3+ AML, where a recent study has demonstrated the benefit of gilteritinib over intensive salvage chemotherapy. In addition, new venetoclax-based regimens are showing promising results. Prof. Craddock then talks on two studies exploring the best conditioning regimens and maintenance strategies post-transplant. He also highlights data showing that sorafenib maintenance is associated with a better survival in patients with FLT3+ AML, and mentions the importance of employing new therapies to manage patients who relapse after transplantation. Finally, Prof. Craddock emphasizes the importance of conducting molecular analyses and translational studies to better understand the molecular basis of relapse. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
